The Guidelines further make clear that discontinuance should be done as soon as it becomes clear the patient is not responding to the treatment modality and that there is no requirement of a full 60-day trial period.  (Practitioner’s point: If the reports do not demonstrate improvement using the criteria noted above, an objection to treatment should be filed and the carrier should push for discontinuance/tapering if no improvement is demonstrated.)